SV2017005441A - Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson - Google Patents

Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson

Info

Publication number
SV2017005441A
SV2017005441A SV2017005441A SV2017005441A SV2017005441A SV 2017005441 A SV2017005441 A SV 2017005441A SV 2017005441 A SV2017005441 A SV 2017005441A SV 2017005441 A SV2017005441 A SV 2017005441A SV 2017005441 A SV2017005441 A SV 2017005441A
Authority
SV
El Salvador
Prior art keywords
parkinson
antagonist
disease
low dose
adhd treatment
Prior art date
Application number
SV2017005441A
Other languages
English (en)
Inventor
Lone Frydelund Larsen
Johan Areberg
Nathalie Breysee
Gamini Chandrasena
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of SV2017005441A publication Critical patent/SV2017005441A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A DOSIS ESPECÍFICAS DE UN ANTAGONISTA DE A2A PARA UTILIZARLO COMO UN MEDICAMENTO Y, EN PARTICULAR, QUE SEAN ÚTILES PARA EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON Y DEL TRASTORNO POR DÉFICIT DE ATENCIÓN CON HIPERACTIVIDAD
SV2017005441A 2014-12-03 2017-05-12 Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson SV2017005441A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201400704 2014-12-03

Publications (1)

Publication Number Publication Date
SV2017005441A true SV2017005441A (es) 2017-08-25

Family

ID=58731664

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2017005441A SV2017005441A (es) 2014-12-03 2017-05-12 Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson

Country Status (25)

Country Link
US (2) US20160158211A1 (es)
EP (1) EP3226863A1 (es)
JP (1) JP2017536400A (es)
KR (1) KR20170090430A (es)
CN (1) CN106999480A (es)
AU (1) AU2015357197A1 (es)
BR (1) BR112017011777A2 (es)
CA (1) CA2966582A1 (es)
CL (1) CL2017001407A1 (es)
CO (1) CO2017004785A2 (es)
CR (1) CR20170221A (es)
DO (1) DOP2017000121A (es)
EA (1) EA201790973A1 (es)
EC (1) ECSP17030050A (es)
IL (1) IL252355A0 (es)
MA (1) MA41090A (es)
MX (1) MX2017007027A (es)
NI (1) NI201700066A (es)
PE (1) PE20170926A1 (es)
PH (1) PH12017500923A1 (es)
SG (1) SG11201704370XA (es)
SV (1) SV2017005441A (es)
TN (1) TN2017000174A1 (es)
TW (1) TW201632186A (es)
WO (1) WO2016087429A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113727999A (zh) 2019-01-11 2021-11-30 奥默罗斯公司 用于治疗癌症的方法和组合物
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CN114917350B (zh) * 2022-06-21 2023-06-13 重庆医科大学附属第二医院 Cftr增强剂在注意缺陷与多动障碍中的应用及产品

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3002283T1 (en) * 2003-12-26 2018-06-29 Kyowa Hakko Kirin Co., Ltd. Thiazole derivatives
ES2658892T3 (es) * 2008-07-23 2018-03-12 Kyowa Hakko Kirin Co., Ltd. Agente terapéutico para la migraña
TWI548411B (zh) * 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
UA110097C2 (uk) * 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою
UA113383C2 (xx) * 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів

Also Published As

Publication number Publication date
IL252355A0 (en) 2017-07-31
US20160158211A1 (en) 2016-06-09
PH12017500923A1 (en) 2017-11-20
CR20170221A (es) 2017-10-05
CN106999480A (zh) 2017-08-01
KR20170090430A (ko) 2017-08-07
CL2017001407A1 (es) 2018-01-05
EP3226863A1 (en) 2017-10-11
TN2017000174A1 (en) 2018-10-19
JP2017536400A (ja) 2017-12-07
MX2017007027A (es) 2017-08-24
WO2016087429A1 (en) 2016-06-09
EA201790973A1 (ru) 2017-10-31
MA41090A (fr) 2017-10-10
TW201632186A (zh) 2016-09-16
ECSP17030050A (es) 2017-08-31
US20180125835A1 (en) 2018-05-10
PE20170926A1 (es) 2017-07-13
SG11201704370XA (en) 2017-06-29
NI201700066A (es) 2018-01-04
BR112017011777A2 (pt) 2018-02-20
AU2015357197A1 (en) 2017-05-25
DOP2017000121A (es) 2017-07-15
CO2017004785A2 (es) 2017-08-31
CA2966582A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
CR20160275A (es) Derivados del sulphamoylpyrrolamide y uso como medicamento para el tratamiento de la hepatitis b
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
SV2017005419A (es) Triazolopirazinonas como inhibidores de pde1
CR20130377A (es) Métodos y productos de fármaco para tratar enfermedad de alzheimer
DOP2015000241A (es) Compuestos de biaril-amida como inhibidores de cinasa
CR20160485A (es) Compuesto de ciclopropanamina y sus usos
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
BR112017008659A2 (pt) ?métodos e compostos de agonista de gip?
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
SV2017005412A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
DOP2017000049A (es) Compuestos tricíclicos que contienen nitrógeno para el tratamiento de la infección por neisseria gonorrhoeae
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
CO2017000950A2 (es) Compuestos que comprenden oligonucleótidos modificados dirigidos a mir-103 y/o mir-107 para trastornos metabólicos
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
SV2017005441A (es) Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
BR112017016333A2 (pt) compostos anticâncer
MX364528B (es) Witanólidos útiles para el tratamiento de enfermedades neurodegenerativas.
DOP2016000179A (es) Hexahidrofuropirroles como inhibidores de pde1
ECSP16094286A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas